Regenxbio Inc
NASDAQ:RGNX
Intrinsic Value
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. [ Read More ]
The intrinsic value of one RGNX stock under the Base Case scenario is 32.33 USD. Compared to the current market price of 16.11 USD, Regenxbio Inc is Undervalued by 50%.
Valuation Backtest
Regenxbio Inc
Run backtest to discover the historical profit from buying and selling RGNX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Regenxbio Inc
Current Assets | 335m |
Cash & Short-Term Investments | 275.3m |
Receivables | 24.8m |
Other Current Assets | 34.9m |
Non-Current Assets | 239m |
Long-Term Investments | 38.9m |
PP&E | 192.6m |
Other Non-Current Assets | 7.5m |
Current Liabilities | 130.3m |
Accounts Payable | 22.8m |
Accrued Liabilities | 56.8m |
Other Current Liabilities | 50.7m |
Non-Current Liabilities | 132m |
Other Non-Current Liabilities | 132m |
Earnings Waterfall
Regenxbio Inc
Revenue
|
90.2m
USD
|
Cost of Revenue
|
-37.2m
USD
|
Gross Profit
|
53m
USD
|
Operating Expenses
|
-321.2m
USD
|
Operating Income
|
-268.1m
USD
|
Other Expenses
|
4.6m
USD
|
Net Income
|
-263.5m
USD
|
Free Cash Flow Analysis
Regenxbio Inc
What is Free Cash Flow?
RGNX Profitability Score
Profitability Due Diligence
Regenxbio Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Regenxbio Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
RGNX Solvency Score
Solvency Due Diligence
Regenxbio Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Regenxbio Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RGNX Price Targets Summary
Regenxbio Inc
According to Wall Street analysts, the average 1-year price target for RGNX is 40.63 USD with a low forecast of 21.21 USD and a high forecast of 57.75 USD.
Ownership
RGNX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RGNX Price
Regenxbio Inc
Average Annual Return | -16.53% |
Standard Deviation of Annual Returns | 21.99% |
Max Drawdown | -78% |
Market Capitalization | 790.1m USD |
Shares Outstanding | 49 042 700 |
Percentage of Shares Shorted | 10.11% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 372 full-time employees. The company went IPO on 2015-09-17. The Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates use adeno-associated virus (AAV) vectors from its gene delivery platform, called NAV Technology Platform. Its product candidate includes RGX-314, RGX-111, RGX-121, RGX-202, RGX 181 and RGX-381. RGX-314 is meant for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) and other anti-VEGF treated conditions. The company is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II). RGX-202 is its product candidate for the treatment of duchenne muscular dystrophy (DMD).
Contact
IPO
Employees
Officers
The intrinsic value of one RGNX stock under the Base Case scenario is 32.33 USD.
Compared to the current market price of 16.11 USD, Regenxbio Inc is Undervalued by 50%.